Faranak Jamali, MD | Authors

Romiplostim for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura

July 14, 2009

On August 22, 2008, the US Food and Drug Administration (FDA) granted marketing approval (licensure) to romiplostim (Nplate, Amgen Inc) for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.